How did LFCR's Q3 2025 EPS forecast compare to past trends?

LFCR's Q3 2025 EPS forecast of -$0.47 represents a significant decline from the previous quarter's EPS of $0.42, indicating a challenging period for the company. This trend is consistent with the overall downward trajectory of the company's EPS, which has been deteriorating since Q3 2023, with a peak loss of -$1.2 in Q3 2024. The recent negative changes in EPS, such as the -22.32% last change from Q2 2025 to Q3 2025, suggest that LFCR is facing considerable difficulties, and the forecast for Q3 2025 reflects this adversity. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |LFCR|LFCR.O|Lifecore Biomedical|2022 Q1|15.789473684210526|-0.32|185| |LFCR|LFCR.O|Lifecore Biomedical|2022 Q2|-188.8888888888889|-1.3|185| |LFCR|LFCR.O|Lifecore Biomedical|2022 Q3|-136.8421052631579|-0.45|185| |LFCR|LFCR.O|Lifecore Biomedical|2023 Q1|-15.624999999999996|-0.37|185| |LFCR|LFCR.O|Lifecore Biomedical|2023 Q2|66.92307692307693|-0.43|185| |LFCR|LFCR.O|Lifecore Biomedical|2023 Q3|-166.66666666666666|-1.2|185| |LFCR|LFCR.O|Lifecore Biomedical|2024 Q1|5.405405405405411|-0.35|185| |LFCR|LFCR.O|Lifecore Biomedical|2024 Q2|190.6976744186047|0.39|185| |LFCR|LFCR.O|Lifecore Biomedical|2024 Q3|135|0.42|185| |LFCR|LFCR.O|Lifecore Biomedical|2025 Q1|-51.428571428571445|-0.53|185|